Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses.
Kasper SM, Meinert P, Kampe S, et al.
Anesthesiology 2003;99(1):42-47.
Review by
The in vitro effects of crystalloids and colloids on coagulation.
Ekseth K, Abildgaard L, Vegfors M, Berg-Johnsen J, Engdahl O
Anaesthesia 2002;57(11):1102-1108.
Review by Mythen MG; Baron JF
Bleeding from endometrial and vaginal malignant tumors treated with activated recombinant factor VII.
Sajdak S, Moszynski R, Opala T
Eur J Gynaecol Oncol 2002;23(4):325-326.
Review by
Treatment of critical bleeding in the future intensive care unit. [Editorial]
Goodnough LT
Intensive Care Med 2002;28(Suppl 2):S221.
Review by Aldouri M
Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta.
Kastrup M, von Heymann C, Hotz H, et al.
Ann Thorac Surg 2002;74(3):910-912.
Review by
Application of recombinant activated factor VII during surgery for a giant skull base hemangiopericytoma to achieve safe hemostasis. Case report.
Gerlach R, Marquardt G, Wissing H, et al.
J Neurosurg 2002;96(5):946-948.
Review by
Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: A pilot study.
Lynn M, Jerokhimov I, Jewelewicz D, et al.
J Trauma 2002;52(4):703-707.
Review by
Effectiveness of combined blood conservation measures in thoracic aortic operations with deep hypothermic circulatory arrest.
Shibata K, Takamoto S, Kotsuka Y, Sato H
Ann Thorac Surg 2002;73(3):739-743.
Review by Regan F
Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation.
Lisman T, Leebeek FWG, Meijer K, Van Der Meer J, Nieuwenhuis HK, De Groot PG
Hepatology 2002;35(3):616-621.
Review by
Inhibition of fibrinolysis by recombinant factor VIIA in plasma from patients with severe hemophilia A.
Lisman T, Mosnier LO, Lambert T, et al.
Blood 2002;99(1):175-179.
Review by
Use of recombinant factor VII in hepatology.
Romero Castro R, Barroso Relinque N, Caunedo Alvarez AC, et al.
Rev Esp Enferm Dig 2001;93(10):664-668.
Review by
Aprotinin in orthotopic liver transplantation: Evidence for a prohemostatic, but not a prothrombotic, effect.
Molenaar IQ, Legnani C, Groenland TH, et al.
Liver Transplant 2001;7(10):896-903.
Review by W. Dietrich
Recombinant activated factor VII (RFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices.
This is a new open-label study, which showed efficacy of rFVIIa in normalising prothrombin time and effective control of bleeding esophageal varices in cirrhotic patients,... Read More
Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects.
Erhardtsen E, Nilsson P, Johannessen M, Thomsen MS
J Clin Pharmacol 2001;41(8):880-885.
Review by M. Aldouri; J. Ingerslev
Hemostatic changes in patients receiving hydroxyethyl starch: The influence of ABO blood group.
Huraux C, Ankri A, Eyraud D, et al.
Anesth Analg 2001;92(6):1396-1401.
Review by Monty Mythen
NATA: Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.
Sitemap
Contact us
- secretary@nataonline.com
-
NATA
Rue de l’Industrie 24
1040 Bruxelles - VAT: 0781668659